Anavex Life Sciences
Yahoo Finance • 21 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at... Full story
Yahoo Finance • last month
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's
[Alzheimers Concept Horizontal] travellinglight * Anavex Life Sciences (AVXL [https://seekingalpha.com/symbol/AVXL]) has formally asked the European Medicines Agency to re-examine its opinion [https://seekingalpha.com/news/4531047-ema-r... Full story
Yahoo Finance • last month
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson'... Full story
Yahoo Finance • last month
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
LOS ANGELES, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex” or “the Company”)... Full story
Yahoo Finance • 2 months ago
SA Quant ranks Goldman's small-cap stocks with largest short interest
[Multi screen fintech investing gold and silver trading on digital screen corporating with AI artificial intelligence financial business data on commodity investment] primeimages Goldman Sachs analysts last week identified 50 small-cap st... Full story
Yahoo Finance • 2 months ago
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson'... Full story
Yahoo Finance • 2 months ago
Anavex Life Sciences GAAP EPS of -$0.11 beats by $0.04
* Anavex Life Sciences press release [https://seekingalpha.com/pr/20319558-anavex-life-sciences-reports-fiscal-2025-fourth-quarter-financial-results-and-provides] (AVXL [https://seekingalpha.com/symbol/AVXL]): Q4 GAAP EPS of -$0.11 beats... Full story
Yahoo Finance • 2 months ago
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
Company to host a webcasttoday at 8:30 a.m. Eastern Time NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing... Full story
Yahoo Finance • 2 months ago
Here are the major earnings before the open Tuesday
Major earnings expected before the bell on Tuesday include: * Alibaba Group Holding Limited (BABA [https://seekingalpha.com/symbol/BABA]) * NIO (NIO [https://seekingalpha.com/symbol/NIO]) * Best Buy Co. (BBY [https://seekingalpha.co... Full story
Yahoo Finance • 2 months ago
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson'... Full story
Yahoo Finance • 2 months ago
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson'... Full story
Yahoo Finance • 2 months ago
Anavex tumbles as Alzheimer’s therapy faces EU rejection
[Alzheimers Concept Horizontal] travellinglight/iStock via Getty Images Anavex Life Sciences (AVXL [https://seekingalpha.com/symbol/AVXL]) lost ~47% in the premarket on Friday after a group of experts appointed by the EU drug regulator, t... Full story
Yahoo Finance • 2 months ago
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease
Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company’s Alzheimer's Disease clinical trial results NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) --... Full story
Yahoo Finance • 2 months ago
Anavex dips amid oral hearing scheduled for lead drug in EU
[An arrow pointing downwards on top of a pile of US dollar bills.] * Shares of Anavex Life Sciences (AVXL [https://seekingalpha.com/symbol/AVXL]) fell as much as ~9% on Monday after the EU drug regulator, the European Medicines Agency (... Full story
Yahoo Finance • 3 months ago
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
ADAS-Cog13 difference −12.78 (P < 0.0001) with oral blarcamesine treatment compared to ADNI control group at Week 144 77.4 Weeks (17.8 Months) ‘time saved’ with oral blarcamesine compared to ADNI Restoring impaired Autophagy − preceding... Full story
Yahoo Finance • 3 months ago
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’
NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson'... Full story
Yahoo Finance • 4 months ago
Why Anavex Is Rising In Pre-market?
(RTTNews) - Anavex Life Sciences (AVXL) announced positive topline results from its placebo-controlled Phase 2 clinical study evaluating ANAVEX3-71 for the treatment of schizophrenia in adults on stable antipsychotic medication. The study... Full story
Yahoo Finance • 4 months ago
Anavex rises after mid-stage trial data for schizophrenia candidate
[Crumpled piece of paper with word Schizophrenia on torn white paper pieces background.] Anavex Life Sciences (NASDAQ:AVXL [https://seekingalpha.com/symbol/AVXL]) traded higher in the premarket on Thursday after the New York-based biotech... Full story
Yahoo Finance • 4 months ago
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program
ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults Oral ANAVEX®3-71 tablet exhibits superior pharmacokinetics compared to the current immediate-release oral capsule, ena... Full story
Yahoo Finance • 4 months ago
Notable Wednesday Option Activity: CLSK, BKD, AVXL
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in CleanSpark Inc (Symbol: CLSK), where a total volume of 108,050 contracts has been traded thus far today, a contract volum... Full story
